Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability

被引:243
作者
Zhuang, Chun-Yang [1 ]
Li, Ning [1 ]
Wang, Mi [1 ]
Zhang, Xiao-Ning [2 ]
Pan, Wei-San [1 ]
Peng, Jun-Jie [1 ]
Pan, Yu-Sheng [1 ]
Tang, Xin [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
[2] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China
关键词
Nanostructure lipid carriers; Vinpocetine; Oral bioavailability; Sustained release; Poorly water-soluble drugs; APOVINCAMINIC ACID; DRUG-RELEASE; FATTY-ACIDS; PHARMACOKINETICS; NANOPARTICLES; FORMULATION; ABSORPTION; METABOLITE; SYSTEMS;
D O I
10.1016/j.ijpharm.2010.05.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study is to develop an optimized nanostructured lipid carriers (NLC) formulation for vinpocetine (VIN), and to estimate the potential of NLC as oral delivery system for poorly water-soluble drug. In this work, VIN-loaded NLC (VIN-NLC) was prepared by a high pressure homogenization method. The VIN-NLC showed spherical morphology with smooth surface under transmission electron microscope (TEM) and scanning electron microscopic (SEM) analysis. The average encapsulation efficiency was 94.9 +/- 0.4%. The crystallization of drug in NLC was investigated by powder X-ray diffraction and differential scanning calorimetry (DSC). The drug was in an amorphous state in the NLC matrix. In the in vitro release study, VIN-NLC showed a sustained release profile of VIN and no obviously burst release was observed. The oral bioavailability study of VIN was carried out using Wistar rats. The relative bioavailability of VIN-NLC was 322% compared with VIN suspension. In conclusion, the NLC formulation remarkably improved the oral bioavailability of VIN and demonstrated a promising perspective for oral delivery of poorly water-soluble drugs. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 31 条
[1]   Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application [J].
Abd Elbary, A ;
Foda, N ;
El-Gazayerly, O ;
El Khatib, M .
ANALYTICAL LETTERS, 2002, 35 (06) :1041-1054
[2]   Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine [J].
Bönöczk, P ;
Gulyás, B ;
Adam-Vizi, V ;
Nemes, A ;
Kárpáti, E ;
Kiss, B ;
Kapás, M ;
Szántay, C ;
Koncz, I ;
Zelles, T ;
Vas, A .
BRAIN RESEARCH BULLETIN, 2000, 53 (03) :245-254
[3]   The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with Solutol HS 15® [J].
Buszello, K ;
Harnisch, S ;
Müller, RH ;
Müller, BW .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 49 (02) :143-149
[4]  
Cavalli R, 1998, PHARMAZIE, V53, P392
[5]   Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine:: Formulation development and in vivo assessment [J].
Chen, Ying ;
Li, Gao ;
Wu, Xianggen ;
Chen, Zhiyu ;
Hang, Jiangeng ;
Qin, Bei ;
Chen, Song ;
Wang, Ruihua .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (01) :118-125
[6]   COMPARATIVE EFFECTS OF VINPOCETINE AND 8-BR-CYCLIC GMP ON THE CONTRACTION AND CA-45-FLUXES IN THE RABBIT AORTA [J].
CHIU, PJS ;
TETZLOFF, G ;
AHN, HS ;
SYBERTZ, EJ .
AMERICAN JOURNAL OF HYPERTENSION, 1988, 1 (03) :262-268
[7]   APPLICATION OF AN ORIGINAL PROCESS FOR OBTAINING COLLOIDAL DISPERSIONS OF SOME COATING POLYMERS - PREPARATION, CHARACTERIZATION, INDUSTRIAL SCALE-UP [J].
DELABOURET, A ;
THIOUNE, O ;
FESSI, H ;
DEVISSAGUET, JP ;
PUISIEUX, F .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (02) :229-241
[8]   Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules [J].
García-Fuentes, M ;
Torres, D ;
Alonso, MJ .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2003, 27 (2-3) :159-168
[9]   Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system [J].
Hu, FQ ;
Jiang, SP ;
Du, YZ ;
Yuan, H ;
Ye, YQ ;
Zeng, S .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2005, 45 (3-4) :167-173
[10]   Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide [J].
Jacobs, C ;
Kayser, O ;
Müller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) :161-164